Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

5.875 +0.065 (+1.12%)
Streaming Delayed Price Updated: 11:56 AM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Maravai LifeSciences Holdings, Inc. - Class A common stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Maravai LifeSciences Q2 Earnings Call Highlights ↗
Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its... 
Via MarketBeat
Topics Earnings
Maravai Lifesciences (NASDAQ:MRVI) Shares Slide Despite Q2 Beat as Full-Year Revenue Outlook Weighs ↗
Via Chartmill
News headline image
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
From Maravai LifeSciences Holdings, Inc.
Via Business Wire
News headline image
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
From Maravai LifeSciences, Inc.
Via Business Wire
News headline image
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
From TriLink BioTechnologies, LLC
Via Business Wire
Maravai LifeSciences (NASDAQ:MRVI) Surges After Crushing Q1 Estimates and Raising Full-Year Guidance ↗
Via Chartmill
Maravai Lifesciences (NASDAQ:MRVI) Returns to Positive Adjusted EBITDA and Issues 2026 Guidance ↗
Via Chartmill
News headline image
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
From Maravai LifeSciences
Via Business Wire
News headline image
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
From Maravai LifeSciences Holdings, Inc.
Via Business Wire
News headline image
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
From Maravai LifeSciences, Inc.
Via Business Wire
News headline image
Maravai (MRVI) Q1 2026 Earnings Transcript ↗
Maravai (MRVI) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Maravai LifeSciences Q1 Earnings Call Highlights ↗
Maravai LifeSciences (NASDAQ:MRVI) reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from... 
Via MarketBeat
Topics Earnings
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Maravai LifeSciences Reports First Quarter 2026 Financial Results
From Maravai LifeSciences Holdings, Inc.
Via Business Wire
News headline image
Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026
From Maravai LifeSciences, Inc.
Via Business Wire
Top movers in Wednesday's after hours session ↗
Via Chartmill
News headline image
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
From Maravai LifeSciences Holdings, Inc.
Via Business Wire
News headline image
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026
From Maravai LifeSciences, Inc.
Via Business Wire
News headline image
Teleflex Stock Slides 39% in a Year, but This $8.5 Million Buy Signals a Contrarian Bet ↗
This medical device firm supplies hospitals worldwide with single-use products for critical care, surgery, and interventional procedures. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About a New $9 Million Bet on an Energy Distributor Stock ↗
This energy sector distributor delivers maintenance, repair, and supply chain solutions to industrial clients across a global network. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗
Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis. 
Via The Motley Fool
News headline image
Maravai LifeSciences Announces November 2025 Investor Conference Schedule
From Maravai LifeSciences, Inc.
Via Business Wire
News headline image
Maravai LifeSciences (MRVI) Stock Plummets After Q3 2025 Revenue Miss and Weak Guidance ↗
Maravai LifeSciences (MRVI) stock fell after Q3 2025 revenue missed estimates. The company reported a net loss and provided full-year guidance below analyst expectations. 
Via Chartmill
News headline image
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
From Maravai LifeSciences Holdings, Inc.
Via Business Wire
News headline image
MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 6, 2025
From Maravai LifeSciences, Inc.
Via Business Wire
News headline image
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.